Wolfgang Miesbach/LinkedIn
Apr 28, 2026, 05:28
Wolfgang Miesbach: How Can the Sustainable Funding of Transformative Gene Therapies Be Ensured?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Approved Gene Therapy. For Free. In 2026.
Regeneron’s Otarmeni (lunsotogene parvec‑cwha) – the first FDA‑approved gene therapy for genetic hearing loss – will be provided at no cost to clinically eligible patients in the United States.
Under a ‘Most Favored Nation’ (MFN)–style agreement with the U.S. government, linking U.S. prices to the lowest levels observed in comparable high‑income countries, Regeneron has committed to:
- Providing Otarmeni at no cost to eligible U.S. patients (with treatment logistics and administration costs covered through established payer mechanisms).
- Aligning Medicaid pricing – as well as future U.S. launch prices for selected medicines – with international benchmark levels.
- Medicaid is the U.S. public insurance program covering tens of millions of individuals, including low‑income populations, children, people with disabilities, and older adults.
- Expanding U.S.-based manufacturing and repatriating foreign revenues within an ‘America‑first’ pricing framework.
One big question remains:
How can the sustainable funding of transformative gene therapies be ensured in a manner that is equitable for both patients and healthcare systems?”
Stay updated with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support